Orion stock holds steady as the company builds its drug pipeline

Orion stock centers on its pharmaceutical business and investor base, with the Finnish company listed in Helsinki and active in human and veterinary medicines.

Orion stock (ISIN FI0009014377) reflects a Finnish pharmaceutical company whose business spans human and veterinary medicines, active ingredients, and contract manufacturing. The company is listed in Helsinki and serves both prescription and self-care markets.

Business profile

Orion Corporation is best known for developing and commercializing medicines in areas such as oncology, pain and central nervous system treatments, while also supplying animal health products and pharmaceutical ingredients. That mix gives the group exposure to both branded drug sales and broader life-science production.

Investor context

For investors, the structural story is Orion's combination of in-house drug development and diversified healthcare operations. The model is more defensive than that of a pure biotech name, because revenue can come from several product and service categories at once.

Medicines and animal health

Orion's portfolio includes prescription medicines and consumer health products, with a presence in both human and animal care. That breadth matters because it reduces dependence on a single therapeutic area or one product line.

Listing and market view

Orion Corporation shares trade in Helsinki under the ticker ORNBV. As of July 10, 2026, no live price is included here.

Fact box

• Company: Orion Corporation
• ISIN: FI0009014377
• Ticker: ORNBV
• Exchange: Nasdaq Helsinki
• Sector / Industry: Healthcare / Pharmaceuticals
• Index membership: not specified
• Next earnings date: not yet officially scheduled